240 related articles for article (PubMed ID: 34113342)
1. Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells
Niu C; Chen Y; Li M; Zhu S; Zhou L; Xu D; Li Z; Xu J; Li W; Wang Y; Cui J
Front Immunol; 2021; 12():658562. PubMed ID: 34113342
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome.
Cifaldi L; Prencipe G; Caiello I; Bracaglia C; Locatelli F; De Benedetti F; Strippoli R
Arthritis Rheumatol; 2015 Nov; 67(11):3037-46. PubMed ID: 26251193
[TBL] [Abstract][Full Text] [Related]
3. Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody.
Lee HR; Son CH; Koh EK; Bae JH; Kang CD; Yang K; Park YS
Sci Rep; 2017 Sep; 7(1):11075. PubMed ID: 28894091
[TBL] [Abstract][Full Text] [Related]
4. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
5. Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting.
Merkt W; Lorenz HM; Watzl C
Arthritis Res Ther; 2016 Sep; 18(1):206. PubMed ID: 27629249
[TBL] [Abstract][Full Text] [Related]
6. T cells, particularly activated CD4
Wang Z; Chimenti MS; Strouse C; Weiner GJ
Cancer Immunol Immunother; 2022 Feb; 71(2):237-249. PubMed ID: 34110453
[TBL] [Abstract][Full Text] [Related]
7. Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma.
Enqvist M; Jacobs B; Junlén HR; Schaffer M; Melén CM; Friberg D; Wahlin BE; Malmberg KJ
Front Immunol; 2019; 10():2085. PubMed ID: 31572357
[TBL] [Abstract][Full Text] [Related]
8. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.
Niu C; Jin H; Li M; Xu J; Xu D; Hu J; He H; Li W; Cui J
BMC Immunol; 2015 Oct; 16():61. PubMed ID: 26458364
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
10. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
[TBL] [Abstract][Full Text] [Related]
11. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
12. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
[TBL] [Abstract][Full Text] [Related]
13. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
Wang SY; Racila E; Taylor RP; Weiner GJ
Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795
[TBL] [Abstract][Full Text] [Related]
14. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
15. Impairment in cytotoxicity and expression of NK cell- activating receptors on human NK cells following exposure to asbestos fibers.
Nishimura Y; Miura Y; Maeda M; Kumagai N; Murakami S; Hayashi H; Fukuoka K; Nakano T; Otsuki T
Int J Immunopathol Pharmacol; 2009; 22(3):579-90. PubMed ID: 19822075
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection.
Ghosh S; Nandi M; Pal S; Mukhopadhyay D; Chakraborty BC; Khatun M; Bhowmick D; Mondal RK; Das S; Das K; Ghosh R; Banerjee S; Santra A; Chatterjee M; Chowdhury A; Datta S
Clin Microbiol Infect; 2016 Aug; 22(8):733.e9-733.e19. PubMed ID: 27208430
[TBL] [Abstract][Full Text] [Related]
17. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
Arora J; Ayyappan S; Yin C; Smith BJ; Lemke-Miltner CD; Wang Z; Farooq U; Weiner GJ
Blood; 2024 May; 143(18):1816-1824. PubMed ID: 38457360
[TBL] [Abstract][Full Text] [Related]
18. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
19. The effects of IL-17 upon human natural killer cells.
Al Omar S; Flanagan BF; Almehmadi M; Christmas SE
Cytokine; 2013 Apr; 62(1):123-30. PubMed ID: 23490420
[TBL] [Abstract][Full Text] [Related]
20. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
